<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119375">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951170</url>
  </required_header>
  <id_info>
    <org_study_id>ML28703</org_study_id>
    <nct_id>NCT01951170</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis</brief_title>
  <official_title>An Open-Label Study to Evaluate Non-Progression Of Structural Joint Damage Of Subcutaneous Tocilizumab In Patients With Moderate To Severe Active Rheumatoid Arthritis (Ac-Cute)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>Australia: Therapeutic Goods Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, single-arm study will evaluate the efficacy and safety of RoActemra/Actemra
      (tocilizumab) in patients with active moderate to severe rheumatoid arthritis. Patients will
      receive a subcutaneous dose of RoActemra/Actemra 162 mg once weekly. The anticipated time on
      study treatment is 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Absolute change in Genant-modified total Sharp score (mTSS)</measure>
    <time_frame>From screening to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) remission (defined as DAS28&lt;2.6)</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in American College of Rheumatology (ACR20/50/70) response</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in European League Against Rheumatism (EULAR) Response</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total tender joint count (TJC)</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in swollen joint count (SJC)</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Outcomes</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Assessment of immunogenicity</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in rheumatoid arthritis magnetic resonance imaging scoring system (RAMRIS) scoring of erosions, synovitis, cartilage loss and osteitis.</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RoActemra/Actemra Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab (RoActemra/Actemra)</intervention_name>
    <description>tocilizumab 162 mg subcutaneously once weekly for 24 weeks</description>
    <arm_group_label>RoActemra/Actemra Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients at least 18 years of age

          -  Patients with a diagnosis of active moderate to severe rheumatoid arthritis (RA)

          -  Oral corticosteroids and nonsteroidal anti-inflammatory are permitted if on a stable
             dose regimen for &gt;/= 4 weeks prior baseline

          -  Permitted non-biologic DMARDs used alone or in combination are allowed if at a stable
             dose for at least 4 weeks prior to baseline

          -  Receiving treatment on an outpatient basis, not including RoActemra/Actemra

          -  Females of childbearing potential and males with female partners of childbearing
             potential may participate in this study only if using a reliable means of
             contraception for at least 5 months following the last dose RoActemra/Actemra

          -  Previous or current treatment with methotrexate with an inadequate response to
             methotrexate, intolerance to methotrexate or treatment with methotrexate was
             considered as inappropriate

          -  Evidence of i or more erosions in hands or feet assessed by X-ray attribute to RA or
             MRI of wrist of MCP joints of dominant hand

        Exclusion Criteria:

          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned
             major surgery within 6 months following baseline

          -  Rheumatic autoimmune disease other than rheumatoid arthritis

          -  Functional Class IV as defined by the ACR Classification of Functional Status in
             Rheumatoid Arthritis

          -  Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of
             16

          -  Prior history of current inflammatory joint disease other than RA

          -  Exposure to RoActemra/Actemra at any time prior to baseline

          -  Treatment with any investigational agent within 4 weeks (or five half-lives of the
             investigational drug, whichever is longer) of screening

          -  Previous treatment with any cell-depleting therapies

          -  Treatment with IV gamma globulin, plasmapheresis within 6 months of baseline

          -  Intraarticular (IA) or parenteral corticosteroids within 4 weeks prior to baseline

          -  Any previous treatment with alkylating agents such as chlorambucil, or with total
             lymphoid irradiation

          -  Treatment with 2 or more anti-TNFs or any other biologic agent at any time prior to
             screening

          -  Evidence of serious uncontrolled concomitant disease (e.g., cardiovascular, nervous
             system, pulmonary)

          -  History of diverticulitis, diverticulosis requiring antibiotic treatment, or chromic
             ulcerative lower GI disease such as Crohn's disease, ulcerative colitis, or other
             symptomatic lower GU conditions that might predispose to perforation

          -  Known active current or history of recurrent infections
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML28703 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7100</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivanhoe</city>
        <state>Victoria</state>
        <zip>3079</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Morwell</city>
        <state>Victoria</state>
        <zip>3842</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
